The retrospective analysis revealed minimal adverse events such as pain, mild erythema, and edema, which were transient and resolved without intervention in a day or two. To date, no cases have recurred, “which we were surprised by,” Dr. Katz said. “We were surprised that the effect lasted that long.”Dr. Katz disclosed that he has received grant funding from CosmeceuTech, Cynosure, Kythera, Neothetics, and equipment from BTL. He has received consulting fees from DEKA, Allergan, Merz, and Galderma, and has received honoraria from Syneron-Candela and Cynosure. Dr. Katz has served on the advisory board for Allergan, Aliva, Merz, Syneron-Candela, and Valeant, and has served on the promotional speakers bureau for Cynosure.
SOURCE: Katz et. al. ASLMS 2018.